Zaaqoq Akram M, Heinsar Silver, Yoon Hwan-Jin, White Nicole, Griffee Matthew J, Suen Jacky Y, Bassi Gianluigi L, Fanning Jonathon P, Shehatta Ahmad Labib, Alexander Peta M A, Jacobs Jeffrey P, Dalton Heidi J, Lorusso Roberto, Cho Sung-Min, Peek Giles J, Fraser John F
Department of Anesthesiology, Division of Critical Care, University of Virginia, Charlottesville, VA, USA.
Critical Care Research Group, University of Queensland and Adult Intensive Care Service, Prince Charles Hospital Brisbane, QLD, Australia.
Perfusion. 2025 May;40(4):993-1003. doi: 10.1177/02676591241267228. Epub 2024 Jul 24.
ObjectiveThe outcomes of COVID-19 patients on venovenous extracorporeal membrane oxygenation (VV-ECMO) varied. We aim to investigate the variability concerning location and timeframe. We conducted a retrospective analysis of data from 351 institutions in 53 countries. The primary outcome was survival to hospital discharge or death up to 90 days from ECMO start. The associations between calendar time (month and year) of ECMO initiation and the primary outcome were examined by Cox regression modeling. Multivariable survival analyses were adjusted for the time of ECMO start, age, body mass index, APACHE II, SOFA, and the duration of mechanical ventilation before ECMO.Results1060 adult COVID-19 patients enrolled in the COVID-19 Critical Care Consortium (COVID Critical) international registry and required VV-ECMO support. The study period is from January 2020 to December 2021. The median age was 51 years old, and 70% were male patients. Most patients were from Europe (39.3%) and North America (37.4%). The in-hospital mortality of the entire cohort was 47.12%. In North America and Europe, there was an increased probability of death from May 2020 through February 2021. Latin America showed a steady rate of survival until late in the study. South Asia, the Middle East, and Africa showed an increased chance of mortality around May 2020. In the Asian-Pacific region, after February 2021, there was an increased probability of death. The time of ECMO initiation and advanced patient age were associated with increased mortality.ConclusionVariability in the outcomes of COVID-19 patients on VV-ECMO existed within different regions. This variability reflects the differences in resources, policies, patient selection, management, and possibly COVID-19 virus subtypes. Our findings might help guide global response in the future by early adoption of patient selection protocols, worldwide policies, and delivery of resources.
目的
接受静脉-静脉体外膜肺氧合(VV-ECMO)治疗的新型冠状病毒肺炎(COVID-19)患者的治疗结果各不相同。我们旨在研究其在地点和时间范围方面的变异性。我们对来自53个国家351家机构的数据进行了回顾性分析。主要结局是自ECMO开始至90天内出院存活或死亡。通过Cox回归模型检验ECMO启动的日历时间(月份和年份)与主要结局之间的关联。多变量生存分析针对ECMO开始时间、年龄、体重指数、急性生理与慢性健康状况评分系统II(APACHE II)、序贯器官衰竭评估(SOFA)以及ECMO前机械通气时间进行了校正。
结果
1060例成年COVID-19患者纳入了COVID-19重症监护联盟(COVID Critical)国际登记处并需要VV-ECMO支持。研究期间为2020年1月至2021年12月。中位年龄为51岁,男性患者占70%。大多数患者来自欧洲(39.3%)和北美(37.4%)。整个队列的院内死亡率为47.12%。在北美和欧洲,2020年5月至2021年2月期间死亡概率增加。拉丁美洲在研究后期显示出稳定的生存率。南亚、中东和非洲在2020年5月左右死亡率增加。在亚太地区,2021年2月之后死亡概率增加。ECMO启动时间和患者高龄与死亡率增加相关。
结论
不同地区接受VV-ECMO治疗的COVID-19患者的治疗结果存在变异性。这种变异性反映了资源、政策、患者选择、管理以及可能的COVID-19病毒亚型方面的差异。我们的研究结果可能有助于通过尽早采用患者选择方案、全球政策和资源分配来指导未来的全球应对措施。